Drug intelligence / Profile preview

HLB1-006

Development stage: Preclinical
Lead developer: Huonslab
Modality: Peptides

Overview

HLB1-006 is a preclinical-stage therapeutic candidate developed by Huonslab, a subsidiary of Huons Global. It functions as a long-acting dual agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon-like peptide-2 receptor (GLP-2R). The drug is intended for the treatment of short bowel syndrome (SBS), aiming to improve intestinal adaptation, enhance nutrient absorption, and reduce the need for parenteral nutrition in affected patients by leveraging the synergistic effects of GLP-1R and GLP-2R activation.

Targets

GLP1R (GLP-1R)GLP2R (Glucagon-like peptide 2 receptor)

Beyond the preview

Go deeper on HLB1-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLB1-006.

Explore the full profile